Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 50/100

Failure Rate

11.1%

1 terminated/withdrawn out of 9 trials

Success Rate

66.7%

-19.9% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

50%

1 of 2 completed trials have results

Key Signals

3 recruiting1 with results

Enrollment Performance

Analytics

Phase 1

5(55.6%)

Phase 2

4(44.4%)

9Total

Phase 1(5)

Phase 2(4)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (9)

Showing 9 of 9 trials

NCT07419841Phase 1Recruiting

A Phase 1 Study of the Safety and Tolerability of CTX-10726

Role: lead

NCT06150664Phase 1Recruiting

A Phase 1 of CTX-8371 in Patients With Advanced Malignancies

Role: lead

NCT05513742Phase 2Completed

A Study of CTX-009 in Adult Patients With Metastatic Colorectal Cancer

Role: lead

NCT07684170Phase 2Not Yet Recruiting

Study of CTX-471 in Patients With Neural Cell Adhesion Molecule (NCAM) Positive Neuroendocrine Neoplasms

Role: lead

NCT07662031Phase 2Not Yet Recruiting

Tovecimig Plus FOLFIRI in Second Line Metastatic Colorectal Cancer

Role: collaborator

NCT07392957Phase 1Recruiting

Safety and Efficacy of CTX-009 With or Without CTX-471 for Recurrent Glioblastoma

Role: collaborator

NCT05506943Phase 2Active Not Recruiting

A Study of CTX-009 in Combination With Paclitaxel in Adult Patients With Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers (COMPANION-002)

Role: lead

NCT03881488Phase 1Completed

Study of CTX-471 as a Monotherapy or in Combination With Pembrolizumab in Patients Post PD-1/PD-L1 Inhibitors in Metastatic or Locally Advanced Malignancies

Role: lead

NCT04492033Phase 1Terminated

A Study of CTX-009 (ABL001) in Combination With Irinotecan or Paclitaxel in Advanced or Metastatic Solid Tumor Patients

Role: collaborator

All 9 trials loaded